ARCTURUS THERAPEUTICS HOLDINGS INC. Form 8-K (Sept. 30, 2020)

Summary

Current report on Form 8-K of Arcturus Therapeutics Holdings Inc., date of report September 30, 2020, filed under Item 8.01, Other Events. It states that on October 2, 2020 a wholly owned subsidiary of the company was awarded a grant from the Singapore Economic Development Board for up to S$9.3 million (approximately US$6.7 million) to support development of a LUNAR-COV19 vaccine candidate, payable in two installments on milestones. It also states that on September 30, 2020 the subsidiary received a final payment of approximately $5.2 million from the Board under a separate grant dated March 4, 2020. The signature block shows /s/ Joseph E. Payne, Chief Executive Officer.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event
reported): September 30, 2020

ARCTURUS THERAPEUTICS HOLDINGS INC.

(Exact name of registrant as specified
in its charter)

Delaware | 001-38942 | 32-0595345
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.)

10628 Science Center Drive , Suite 250

San Diego , California 92121

(Address of principal executive offices)

Registrant’s telephone number,
including area code: (858) 900-2660

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common stock, par value $0.001 per share | ARCT | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

New Singapore Grant

On October 2, 2020, a wholly-owned subsidiary of Arcturus Therapeutics
Holdings Inc. (the “Company”) was awarded a grant (the “Grant”) from the Singapore Economic Development
Board (the “EDB”) to support the further development of a LUNAR-COV19 vaccine candidate. The Grant provides for up
to S$9.3 million (approximately US$6.7 million) to support the development of the vaccine candidate.

The Grant will be paid in two installments upon the achievement
of certain milestones related to the progress of the development of the vaccine candidate.

Prior Singapore Grant

On September 30, 2020, a wholly-owned subsidiary of the Company
received a final payment of approximately $5.2 million from the EDB, pursuant to a separate and previously disclosed grant dated
March 4, 2020, to support the further development of a LUNAR-COV19 vaccine candidate.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. | Description of Exhibit
104 | Cover Page to this Current Report on Form 8-K in Inline XBRL

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Arcturus Therapeutics Holdings Inc.
Date: October 2, 2020
By: | /s/ Joseph E. Payne
Name: | Joseph E. Payne
Title: | Chief Executive Officer

File and source

File

SEC_ARCT_8-K_filed2020-10-02_0001193805-20-001229.htm

Size

23,032 bytes

SHA-256

f492cc0bccb7be67e55d4404787ff9d645953a9b8b6d6db0a07dd04a39e41589

Our copy

SEC_ARCT_8-K_filed2020-10-02_0001193805-20-001229.htm

Original

www.sec.gov